Tykerb — Medica
Rectal cancer
Initial criteria
- age ≥ 18 years
- unresectable, advanced, or metastatic disease
- human epidermal growth factor receptor 2 (HER2)-amplified disease
- wild-type RAS and BRAF disease
- EITHER tried at least one chemotherapy regimen (e.g., fluoropyrimidine, oxaliplatin, irinotecan, FOLFOX, CapeOX) OR not a candidate for intensive therapy per prescriber
- used in combination with trastuzumab
- has not been previously treated with a HER2-inhibitor (examples: trastuzumab products, neratinib, ado-trastuzumab emtansine, pertuzumab, fam-trastuzumab deruxtecan-nxki)
Approval duration
1 year